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The presence of bone metastasis is a relevant prognostic fac-
tor for cancer patients, and the skeleton is a common site of dis-
tant metastasis in cases of advanced-stage neoplasias. Recent de-
velopments in oncological treatments have led to a significant in-
crease in patients’ survival. On the other hand, much of the mor-
bidity and disability in such patients is caused by metastatic bone
disease. Thus an appropriate assessment of the skeleton for early
detection of bone metastasis is essential for correct clinical deci-
sions making in order to provide patients with appropriate treat-
ment and better quality of life.
Bone scintigraphy (BS) with 99mTc-labeled radiopharmaceu-
ticals, such as 99mTc-MDP, has been extensively utilized for the
diagnosis of bone metastasis, and plays a relevant role in the ini-
tial assessment and follow-up of cancer patients. In spite of its
relatively high sensitivity, the accuracy of BS is compromised by
its limited spatial resolution(1). The specificity is frequently low as
the skeleton may be affected by different diseases with no specific
scintigraphic findings(2). For this reason, about one third of BSs
present inconclusive results for bone metastasis, which implies the
necessity of additional procedures for a definite diagnosis or for
anatomical correlation, namely radiography, computed tomogra-
phy, magnetic resonance imaging and biopsy(3,4). The routine use
of tomographic images such as SPECT/CT (single photon emission
computed tomography/computed tomography) is also helpfull, but
it significantly increases imaging acquisition time, particularly in
cases where several segments of the skeleton must be scanned.
Positron emission tomography/computed tomography (PET/CT)
with the radiopharmaceutical sodium fluoride labeled with fluorine-
18 (18F-NaF) has been utilized in the assessment of bone metasta-
sis in a variety of malignancies(4–6). The fast and intense 18F-fluo-
ride uptake by active osteoblastic lesions and by the osteoblastic
component of osteolytic lesions occurs due 18F-fluoride ions ex-
change with the hydroxyl groups in hydroxyapatite crystals. The
method accuracy is quite high and several studies demonstrate
that 18F-fluoride PET/CT is more sensitive and specific than BS to
identify bone metastases due its higher spatial resolution and to
the more favorable biokinetics of the radiopharmaceutical(4–6).
In Brazil the availability of 18F-fluoride is limited, in spite of
being produced for many years by Instituto de Pesquisas Energéticas
e Nucleares (Ipen). Except for Ipen, all the other ten centers in-
volved in the production of 18F-fluorodeoxyglucose (18F-FDG) do
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not commercialize 18F-fluoride, despite the simplicity of its pro-
duction. Certainly, the main reason for that is the low demand for
18F-fluoride PET/CT scan since it is not covered by both public and
private health care systems. In fact, the cost-effectiveness of 18F-
fluoride PET/CT is still to be established, particularly in Brazil. The
cost of the radiopharmaceutical 18F-fluoride is higher than that of
MDP-99mTc utilized in BS and, in addition, the operational cost of
a PET/CT procedure is also higher than that of a scintillation cam-
era. In this context, the time spent to perform a BS or a 18F-NaF
PET/CT becomes one of the main factors that could balance the
overall costs involved in the performance of each of the two proce-
dures. Such an issue is the core of an extensive and definitive study
developed by Ordones et al. and published in the previous issue of
Radiologia Brasileira(7).
The authors sought to establish the possibility of excluding lower
limbs images from whole-body 18F-fluoride PET/CT scans as a means
to reduce imaging acquisition time by 25% in the investigation of
bone metastases. As much as one thousand whole-body 18F-fluo-
ride PET/CT scans were reviewed by the authors and only three cases
of bone metastases exclusively in the lower limbs were observed;
and one of such lesions was not a true bone metastasis, rather, it
was a soft tissue metastasis infiltrating adjacent bone tissue. Thus,
the prevalence of this type of lesion corresponded to only 0.2%.
Also, it is important to highlight that the two mentioned true ex-
clusive lower limb metastasis found by the authors would have been
detected at images acquired up to the root of the thighs, which
has already been traditionally done and accepted for many years
worldwide for most indications of 18F-FDG PET/CT scans(8).
Generally, a BS is obtained three hours after radiopharma-
ceutical administration, and whole-body and additional static im-
ages acquisition takes about 30 minutes to be completed. As a
SPECT or SPECT/CT acquisition is added, the patient remains in
the examination room for at least additional 15 minutes. As nec-
essary, further correlation with radiography, CT or magnetic reso-
nance imaging is also performed, thus generating additional time
and costs. On the other hand, a 18F-fluoride PET/CT scan can be
initiated 30-60 minutes after radiopharmaceutical administration.
An acquisition up to the proximal femurs as proposed by Ordones
et al.(7) does not take more than 12 minutes to be completed.
Therefore, it might take less than one hour between 18F-fluoride
injection and the patient discharge after image acquisition. It is
possible to perform PET/CT scans in up to four patients per hour,
which corresponds to at least twice the number of BSs performed
during an equal period of time, particularly in cases where SPECT
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images are acquired. The acquisition of additional images, frequently
needed in BSs, is almost never necessary in a 18F-fluoride PET/CT
scan, and the procedure is completed with all the possible corre-
lations with CT already performed – at least for anatomical corre-
lation -, which considerably reduces the necessity of other imag-
ing procedures. As noted by the authors, time savings also provide
radiopharmaceutical savings, since 18F half-life is < 2 hours (in
Brazil, multiple doses are provided in a single vial and they are
locally fractionated in the PET/CT department, so as more scans
can be performed with the activity of a single vial, provided each
scanning time is shortened).
Currently, 18F-fluoride PET/CT is considered to be the most com-
prehensive imaging modality to evaluate metastatic bone disease(9).
The inclusion of such imaging method in the oncological routine
depends on the establishment of practical and effective protocols
whose costs are acceptable by the health care system. Therefore,
it is clear the relevance of the study developed by Ordones et al.
as a support for the incorporation of 18F-fluoride PET/CT imaging
into the clinical practice.
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